
Tranexamic acid in Major orthopaedic surgery

V.Ramesh Consultant Anaesthetist Royal National Orthopaedic Hospital Jan 2015

Definition of major orthopaedic surgery

- Spinal fusion
- Total hip replacements
- Total knee replacements
- What about acute trauma and multiple fractures?

Sacrectomy for osteosarcoma, total femoral replacements





Hoffmann C et al. J Bone Joint Surg Am 2006;88:575-582



©2006 by The Journal of Bone and Joint Surgery, Inc.







Tranexamic Acid





Diagram of the mechanism of action of tranexamic acid. A, Activation of fibrinolysis. B, Inhibition of fibrinolysis. The

Dunn CJ, Goa KL. Drugs. 1999;57:1005-1032



Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)


Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K



- Do antifibrinolytics reduce allogenic blod transfusion in orthopedic surgery?- Meta-analysis.
 - Zufferey et al. Anesthesiology 2006;105:1034-46
- Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials.
 - Kagoma et al.Thrombosis Research.2009; 123:687-696

Both conclude: TXA reduces bleeding and transfusion

- Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement
 - Sukeik et al. JBJS(Br) 2011;93:39-46



Spine Surgery

- Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children
 - systematic review cochrane database, 2008
- Use of Antifibrinolytic agents in spine surgery-a metaanalysis.
 - Gill JB et al. J bone and Joint Surgery Am. 2008;90:2399-2407
- Tranexamic acid reduces blood loss in adult patients having spinal fusion surgery.
 - Wong et al. Anesth Analg 2008;107:1479-86


Systematic Review and Meta-Analysis of Perioperative Intravenous Tranexamic Acid Use in Spinal Surgery 2013

The blood loss was reduced in spinal surgery patients with perioperative IV TXA treatment.

Also the percentage of spinal surgery patients who required blood transfusion was significantly decreased.

Further evaluation is required to confirm our findings before TXA can be safely used in patients undergoing spine surgery.

The Aprotinin Story



What do we know?

Onset of action: 5-15 minutesDuration: 3 hoursProtein binding: about 3%Metabolism: T1/2 is 2-3 hoursExcretion: Urine (>95% unchanged).

Suggested Dosage

1g IV over 10-20 mins to avoid hypotension. Exclusion criteria

- DVT/PE with in 12 months or on anticoagulants.
- Cardiac stent or Ischaemic stroke within 1 yr.
- Relative criteria
- Renal impairment.
- History of seizures.
- Thromboembolic or vascular disease.

Side effects

- Ocular Colour vision loss, blurred vision and/or vision loss!!
- Seizure Probably neuronal GABA inhibition
- Renal impairment?

Seizures with TXA

- Sander et al.
 - Critical Care. 2010;14:R148
- Murkin et al.
 - Anesth Analg. 2010;110:350-353
- Keyl et al.
 - Eur. J. Cardiothoracic Surg. 2011;39:114-121
- Martin et al.
 - J. Cardiothoracic and vascular anaesthesia.2011;25(1): 20-25

Seizures with TXA

- Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis.
 - Ngagge DL, Bland JM. Eur J. of Cardio-thoracic Surgery.2010;37:1375-1383

Tranexamic acid can cross the BBB when it is compromised.

TXA binds competitively in a dose dependent fashion to GABA type A receptors, which results in reduced inhibitory activity and increased neuronal excitation.

There are reports of TXA causing seizures when in direct contact with the CNS of animals and humans.

Tranexamic acid in trauma?

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2)

Randomised controlled trial

274 hospitals

40 countries

202211 adult trauma patients with, or at risk of, significant bleeding were randomly assigned within 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h) or matching placebo.

Both participants and study staff were masked

Tranexamic acid safely reduced the risk of death in bleeding trauma patients in this study. No statistical difference in RBC transfusions between groups.

CRASH-2

The primary outcome was death in hospital within 4 weeks of injury, and was described with the following categories: bleeding, vascular occlusion (myocardial infarction, stroke and pulmonary embolism), multiorgan failure, head injury, and other.

All-cause mortality was significantly reduced with tranexamic acid

The risk of death due to bleeding was significantly reduced

Based on the results of the CRASH-2 Trial, Tranexamic acid was added to the World Health Organization list of essential medicines in March 2011.

Negatives of Crash 2

•Only approximately 5% of patients had bleeding as a cause of death.

•No data regarding injury severity of the patient cohort.

•No data regarding shock in the patient cohort (i.e. lactate and base deficit) and there was the inability to determine if the cohorts were similar.

•Small sample size of hypotensive (SBP < 90 mm Hg) (31.5%) and tachycardic (HR>107) (48%) patients which were the target populations.

•The most common cause of death was traumatic brain injury (TBI).

•TXA did not reduce blood transfusions. Only 50% of study cohort received blood transfusions.

•No adverse events were regarded as serious, unexpected, or suspected to be related to the study treatment.

•Effect size was small. This effect was statistically significant but not a dinically meaningful finding. The study determined a 0.8% absolute reduction in "death caused by bleeding".

Negatives of Crash 2

Re-examination of the 1063/3076 deaths (35%) that resulted from bleeding found that the benefit from TXA was greatest when it was given early \leq 1h, but when given more than 3 hours after injury, an unexpected and unexplained increase in deaths due to bleeding was observed.



The Promise

"We promise to consider the new knowledge on tranexamic acid in bleeding trauma patients and to use it to improve trauma care at this hospital."

A Promise to Save 100,000 Trauma Victims

We now know that injury robs humanity of some 300 million years of healthy life per annum, being responsible for 11% of DALYs world-wide. A Road traffic crashes are the number one killer for young people and account for nearly one third of the world injury burden, a total of 76 million DALYs in 2010, up from 57 million in 1990. Most of the victims are young, many with families that depend on them... more

The Evidence for Tranexamic Acid

Download a list of papers, evidence for using tranexamic acid for trauma injuries:

._The_CRASH-2_trial_tranexamic_acid_in_trauma.pdf

2._The_CRASH-2_trial_-_importance_of_early_treatment.pdf

Tranexamic_acid_is_highly_cost effective.pdf

More

Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study

- **Patients** A total of 896 consecutive admissions with combat injury, of which 293 received TXA, were identified from prospectively collected UK and US trauma registries.
- Main Outcome Measures Mortality at 24 hours, 48 hours, and 30 days and the influence of TXA administration on postoperative coagulopathy and the rate of thromboembolic complications.
- **Results**. The relative reduction in mortality was 6.7% and those who received tranexamic acid had less blood products.
- The NNT was 1:7 but 1:67 in the CRASH-2 trial

Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study

This study also showed that the rates of PE and DVT among patients who received tranexamic acid were, respectively, 9 and 12 times the rates amongst those who did not.

What do the others think?

The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013 Feb;148(2):127-36.

Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage study (the PATCH-Trauma study), 4-year, 1200patient, multicentre trial in Australia and New Zealand. Started recruitment in 2013.

Tranexamic acid in Trauma

How Did It Reduce Mortality?

•Is it caused by an attenuated inflammatory response achieved in part through reduction of circulating plasmin levels

•TXA, inhibits plasmin, which is known to induce proinflammatory effects by activation of monocytes, neutrophils, platelets, and endothelial cells and complement releasing lipid mediators and cytokines.

Anti-inflammatory effect

- Casati V, Della Valle P, Benussi S, et al. Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: comparison between on-pump and off-pump techniques. JThorac Cardiovasc Surg. 2004;128(1):83-91
- Jmenez JJ, Iribarren JL, Lorente L, et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. *Cit Care*. 2007;11(6):R117

Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis. <u>Crit Care.</u> 2007

In the case control study, 165 patients were studied.

In the TA group, we observed a significant reduction in the incidence of VS(P=0.003), the use of norepinephrine (P=0.029), and time on mechanical ventilation (P=0.018).

Sgnificantly lower D-dimer, plasminogen activator inhibitor 1, and creatine-kinase levels and a trend toward lower levels of soluble tumor necrosis factor receptor and interleukin-6 within the first 24 hours after CPB.

An anti-inflammatory role for tranexamic acid in cardiac surgery? Heidi J Robertshaw Orit care 2008

Pro and anti-inflammatory cytokines are elevated after surgery.

The use of tranexamic acid can attenuate this inflammation revelas a glimpseof how the fibrinolytic and inflammatory pathway could be interlinked.

It remains unclear whether the mortality benefit from TXA is from reversal of fibrinolysis or whether an inflammatory or immune modulation is the underlying mechanism.

- How does it act? Why is it different from aprotonin? Does that matter?
- What complications?
- What evidence apart from crash 2?
- What dosage? Bolus and/or infusion
- Does it stop bony bleeding? Soft tissue bleeds
- Should it be given because surgeon requests it?
- Does it change TEG?

• Future research

• The relation between age and mortality needs further exploration. A better understanding of the mechanism by which age is associated with increasing mortality could lead to effective interventions to improve the outcome in this vulnerable population. As we were able to validate the model only in patients from high income regions, future studies should also explore its performance in low and middle income countries. Finally, future research should evaluate whether the use of this prognostic model in dinical practice has an effect on the management and outcomes of trauma patients.25

Antifibrinolytic agents in current anaesthetic practice Table 2

Trauma and orthopaedic surgery. AP, aprotinin; TXA, tranexamic acid; EACA, ε-aminocaproic acid

Author Year Study population Main findings

Shakur and colleagues⁷⁵ 2010 20 211 *Multicentre, double-blind, placebo-controlled RCT*

All-cause mortality and risk of death because of bleeding was significantly reduced in trauma patients with TXA vs placebo; no increased risk of thromboembolic events

Roberts and colleagues⁷⁶ 2011 20 211 *Multicentre, double-blind, placebo-controlled RCT; subgroup analysis* Risk of death is reduced if TXA is given within 3 h after trauma; later administration is associated with increased risk of death

Roberts and colleagues⁷⁷ 2011 20 548 *Cochrane systematic review of four RCTs*

TXA reduced the risk of death in bleeding trauma patients; no reliable data for AP in trauma

CRASH-2 collaborators⁷⁸ 2011 270 Multicentre double-blind, placebo-controlled RCT, nested into CRASH-2

Tranexamic acid did not demonstrate a reduction in intracranial haemorrhage growth or mortality in trauma patients with brain injury

Tzortzopoulou and colleagues⁸⁰ 2008 254 *Cochrane systematic review of six RCTs*

Antifibrinolytic drugs reduced the amount of transfused blood (-327 ml; 95% CI -469.04 to -185.78) and the amount of blood loss (-427 ml; 95% CI -602.51 to -250.56) in paediatric scoliosis surgery

Wong and colleagues⁸¹ 2008 151 Double-blinded, placebo-controlled RCT

Estimated blood loss after spinal fusion in adults was reduced by 25% by TXA; no difference for perioperative transfusion and length of hospital stay

Dhawale and colleagues⁸² 2011 84 *Retrospective database analysis*

Reduced estimated blood loss in children undergoing spinal fusion with prophylactic lysine analogues compared with no treatment

Zufferey and colleagues⁸⁴ 2006 2523 Meta-analysis of 43 RCTs

AP (OR 0.43; 95% CI 0.28–0.64) and TXA (OR 0.17; 95% CI 0.11–0.24) led to a reduction in blood transfusion in orthopaedic surgery, whereas EACA did not

Kagoma and colleagues⁸⁵ 2009 2060 Systematic review of 29 RCTs

Antifibrinolytic agents are associated with reduced blood transfusion after hip and knee replacement; no increased risk for thromboembolic events with antifibrinolytics

Questions?

- Is there a role in low risk patients routinely for major orthopaedic surgery?
- Should it be given to all trauma patients?
- Bolus dose vs infusion?
- Monitoring and targeting treatment
- Role of topical tranexamic acid

Unanswered questions

Anti-inflammatory action Age and antifibrinolytics Dosage, efficacy and safety